Please use this identifier to cite or link to this item: https://doi.org/10.1007/s11912-019-0837-8
DC FieldValue
dc.titleThe Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers
dc.contributor.authorKimpo, Miriam Santiago
dc.contributor.authorOh, Bernice
dc.contributor.authorLee, Shawn
dc.date.accessioned2019-11-14T00:11:58Z
dc.date.available2019-11-14T00:11:58Z
dc.date.issued2019-10-01
dc.identifier.citationKimpo, Miriam Santiago, Oh, Bernice, Lee, Shawn (2019-10-01). The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers. CURRENT ONCOLOGY REPORTS 21 (10). ScholarBank@NUS Repository. https://doi.org/10.1007/s11912-019-0837-8
dc.identifier.issn15233790
dc.identifier.issn15346269
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/162106
dc.description.abstract© 2019, The Author(s). Purpose of Review: We aim to review the most recent findings in the use of NK cells in childhood cancers. Recent Findings: Natural killer cells are cytotoxic to tumor cells. In pediatric leukemias, adoptive transfer of NK cells can bridge children not in remission to transplant. Interleukins (IL2, IL15) can enhance NK cell function. NK cell-CAR therapy has advantages of shorter life span that lessens chronic toxicities, lower risk of graft versus host disease when using allogeneic cells, ability of NK cells to recognize tumor cells that have downregulated MHC to escape T cells, and possibly less likelihood of cytokine storm. Cytotoxicity to solid tumors (rhabdomyosarcoma, Ewing’s sarcoma, neuroblastoma) is seen with graft versus tumor effect in transplant and in combination with antibodies. Challenges lie in the microenvironment which is suppressive for NK cells. Summary: NK cell immunotherapy in childhood cancers is promising and recent works aim to overcome challenges.
dc.language.isoen
dc.publisherSPRINGER
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectOncology
dc.subjectNatural killer cells
dc.subjectAdoptive cell therapy
dc.subjectTumor microenvironment
dc.subjectCAR-NK
dc.subjectNK CELLS
dc.subjectANTI-GD2 ANTIBODY
dc.subjectNEUROBLASTOMA PATIENTS
dc.subjectMONOCLONAL-ANTIBODY
dc.subjectTRANSPLANTATION
dc.subjectKIR
dc.subjectCHILDHOOD
dc.subjectCYTOTOXICITY
dc.subjectACTIVATION
dc.subjectEXPRESSION
dc.typeReview
dc.date.updated2019-11-13T10:16:20Z
dc.contributor.departmentPAEDIATRICS
dc.description.doi10.1007/s11912-019-0837-8
dc.description.sourcetitleCURRENT ONCOLOGY REPORTS
dc.description.volume21
dc.description.issue10
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.pdf706.36 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.